Logo image of IPHA

INNATE PHARMA SA-SPONS ADR (IPHA) Stock Fundamental Analysis

NASDAQ:IPHA - Nasdaq - US45781K2042 - ADR - Currency: USD

2.24  -0.02 (-0.88%)

After market: 2.17 -0.07 (-3.13%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to IPHA. IPHA was compared to 571 industry peers in the Biotechnology industry. Both the profitability and financial health of IPHA have multiple concerns. IPHA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year IPHA has reported negative net income.
In the past year IPHA has reported a negative cash flow from operations.
In the past 5 years IPHA always reported negative net income.
IPHA had negative operating cash flow in 4 of the past 5 years.
IPHA Yearly Net Income VS EBIT VS OCF VS FCFIPHA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M 200M

1.2 Ratios

IPHA has a better Return On Assets (-22.48%) than 75.13% of its industry peers.
IPHA has a Return On Equity of -118.25%. This is comparable to the rest of the industry: IPHA outperforms 41.03% of its industry peers.
Industry RankSector Rank
ROA -22.48%
ROE -118.25%
ROIC N/A
ROA(3y)-17.27%
ROA(5y)-15.56%
ROE(3y)-57.01%
ROE(5y)-44.32%
ROIC(3y)N/A
ROIC(5y)N/A
IPHA Yearly ROA, ROE, ROICIPHA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20 -40 -60 -80 -100

1.3 Margins

IPHA has a Gross Margin of 88.00%. This is amongst the best in the industry. IPHA outperforms 91.30% of its industry peers.
IPHA's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for IPHA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 88%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.32%
GM growth 5Y-0.15%
IPHA Yearly Profit, Operating, Gross MarginsIPHA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200 -300 -400

More info and screens

3

2. Health

2.1 Basic Checks

IPHA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IPHA has been increased compared to 1 year ago.
IPHA has more shares outstanding than it did 5 years ago.
The debt/assets ratio for IPHA has been reduced compared to a year ago.
IPHA Yearly Shares OutstandingIPHA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
IPHA Yearly Total Debt VS Total AssetsIPHA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -2.55, we must say that IPHA is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of IPHA (-2.55) is comparable to the rest of the industry.
A Debt/Equity ratio of 2.73 is on the high side and indicates that IPHA has dependencies on debt financing.
IPHA has a Debt to Equity ratio of 2.73. This is amonst the worse of the industry: IPHA underperforms 83.84% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.73
Debt/FCF N/A
Altman-Z -2.55
ROIC/WACCN/A
WACC7.49%
IPHA Yearly LT Debt VS Equity VS FCFIPHA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 2.92 indicates that IPHA has no problem at all paying its short term obligations.
IPHA has a worse Current ratio (2.92) than 66.79% of its industry peers.
IPHA has a Quick Ratio of 2.92. This indicates that IPHA is financially healthy and has no problem in meeting its short term obligations.
IPHA has a worse Quick ratio (2.92) than 64.65% of its industry peers.
Industry RankSector Rank
Current Ratio 2.92
Quick Ratio 2.92
IPHA Yearly Current Assets VS Current LiabilitesIPHA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

IPHA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 46.50%, which is quite impressive.
Looking at the last year, IPHA shows a very negative growth in Revenue. The Revenue has decreased by -43.07% in the last year.
IPHA shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -8.27% yearly.
EPS 1Y (TTM)46.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1531.56%
Revenue 1Y (TTM)-43.07%
Revenue growth 3Y-2.59%
Revenue growth 5Y-8.27%
Sales Q2Q%-76.54%

3.2 Future

The Earnings Per Share is expected to grow by 36.16% on average over the next years. This is a very strong growth
Based on estimates for the next years, IPHA will show a very strong growth in Revenue. The Revenue will grow by 26.19% on average per year.
EPS Next Y28.59%
EPS Next 2Y39.4%
EPS Next 3Y36.16%
EPS Next 5YN/A
Revenue Next Year-18.02%
Revenue Next 2Y28.57%
Revenue Next 3Y34.8%
Revenue Next 5Y26.19%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IPHA Yearly Revenue VS EstimatesIPHA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M
IPHA Yearly EPS VS EstimatesIPHA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 0.2 -0.2 -0.4 -0.6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

IPHA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IPHA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IPHA Price Earnings VS Forward Price EarningsIPHA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IPHA Per share dataIPHA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4

4.3 Compensation for Growth

A more expensive valuation may be justified as IPHA's earnings are expected to grow with 36.16% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.4%
EPS Next 3Y36.16%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IPHA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INNATE PHARMA SA-SPONS ADR

NASDAQ:IPHA (2/21/2025, 8:00:02 PM)

After market: 2.17 -0.07 (-3.13%)

2.24

-0.02 (-0.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2024-11-13/bmo
Earnings (Next)03-27 2025-03-27/amc
Inst Owners10.33%
Inst Owner Change-42.04%
Ins Owners2.48%
Ins Owner ChangeN/A
Market Cap187.74M
Analysts75.56
Price Target5.27 (135.27%)
Short Float %0.24%
Short Ratio0.25
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.57%
PT rev (3m)-4.83%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)1.23%
EPS NY rev (3m)3.41%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.75%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.23
P/FCF N/A
P/OCF N/A
P/B 6.24
P/tB 6.27
EV/EBITDA N/A
EPS(TTM)-0.42
EYN/A
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)-0.25
FCFYN/A
OCF(TTM)-0.22
OCFYN/A
SpS0.31
BVpS0.36
TBVpS0.36
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -22.48%
ROE -118.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 88%
FCFM N/A
ROA(3y)-17.27%
ROA(5y)-15.56%
ROE(3y)-57.01%
ROE(5y)-44.32%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.32%
GM growth 5Y-0.15%
F-Score2
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 2.73
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 89.84%
Cap/Sales 9.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.92
Quick Ratio 2.92
Altman-Z -2.55
F-Score2
WACC7.49%
ROIC/WACCN/A
Cap/Depr(3y)25.89%
Cap/Depr(5y)98.67%
Cap/Sales(3y)5.93%
Cap/Sales(5y)26.56%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1531.56%
EPS Next Y28.59%
EPS Next 2Y39.4%
EPS Next 3Y36.16%
EPS Next 5YN/A
Revenue 1Y (TTM)-43.07%
Revenue growth 3Y-2.59%
Revenue growth 5Y-8.27%
Sales Q2Q%-76.54%
Revenue Next Year-18.02%
Revenue Next 2Y28.57%
Revenue Next 3Y34.8%
Revenue Next 5Y26.19%
EBIT growth 1Y-52.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-18.08%
EBIT Next 3Y46.8%
EBIT Next 5YN/A
FCF growth 1Y25.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.75%
OCF growth 3YN/A
OCF growth 5YN/A